Recently, resmetirom, a drug targeting the thyroid hormone receptor beta (THRβ) NR, has become the first FDA-approved drug for MASLD, following positive results from the phase III MAESTRO-NASH trial10. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.